Structure of Retro94
Inventors have developed a compound, Retro94, that inhibits human cytomegalovirus (HCMV) replication with high potency and low toxicity. in vitro, the compound was shown to reduce production of infectious virions by greater than two fold.
Application & Market Utility
Current treatments for HCMV suffer limitations. Foscarnet and Cidofovir are potent polymerase inhibitors that are not specific to viral polymerases causing high toxicity. HCMV has developed resistance to Ganciclovir. Novel approaches are required to effectively fight HCMV.
Testing its efficacy on other herpesviruses including VZV, the cause of chicken pox and shingles. Patent pending. Seeking licensing opporunities and funding.